DRUG · Bright Minds Biosciences Inc. · Documents

Bright Minds Biosciences Inc. said the FDA partially held the BMB-101 IND for Developmental and Epileptic Encephalopathies, citing mouse toxicity and inadequate pharmacokinetic and juvenile toxicity data for pediatric enrollment; other ongoing clinical trials are believed unaffected.

At its March 31, 2026 annual general meeting, Bright Minds Biosciences Inc. elected all six director nominees and appointed De Visser Gray LLP as auditor; 7,877,637 common shares represented 80.49% of votes attached to outstanding shares.

Bright Minds Biosciences Inc. will participate in the FPWR 2026 Research Symposium, October 7-8, and PWS Family Conference, October 9-10. It also agreed to rescind an officer’s option exercise covering 44,500 common shares, which will be returned to treasury and cancelled.